Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ESR1 | P03372 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 3/20 | 0.57 |
| ▸ | PGR | P06401 | 3/20 | 0.57 |
| ▸ | AR | P10275 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547189 | 1.00 | MAPT (0.58) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL10710638 | 0.99 | MAPT (0.57) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL10361012 | 0.97 | LMNA (0.60) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL10360650 | 0.94 | MAPT (0.60) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL4254924 | 0.89 | MAPT (0.59) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL4585647 | 0.89 | MAPT (0.62) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL32662774 | 0.89 | MAPT (0.73) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL6331808 | 0.89 | MAPT (0.73) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL10349557 | 0.88 | MAPT (0.58) | MAPTKMT2AMEN1THRBLMNA | |
| SCHEMBL4585643 | 0.88 | LMNA (0.73) | MAPTKMT2AMEN1LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452175-B2 | Pregnancy hormone combination for treatment of autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-27 | — | — | US | claimed |
| US-20160082017-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-24 | — | — | US | claimed |
| US-6894038-B2 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-17 | — | — | US | claimed |
| EP-1478369-A1 | USE OF BIOGENIC ESTRIOL DIESTER PRODRUGS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20040077614-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | SCHERIGN AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | US | claimed |
| EP-1358881-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | Schering Aktiengesellschaft (DE) | 2003-11-05 | — | — | EP | claimed |
| WO-2003072110-A1 | USE OF BIOGENIC ESTRIOL DIESTER PRODRUGS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-04 | — | — | WO | claimed |
| EP-0163596-B1 | ESTRIOL ESTERS | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-08-16 | — | — | EP | claimed |
| US-4681875-A | CONTRACEPTIVES, GYNECOLOGY | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| EP-3277285-B1 | ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY | UNIV CALIFORNIA (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11865122-B2 | Estrogen therapy for brain gray matter atrophy and associated disability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| EP-3137087-B1 | ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS | UNIV CALIFORNIA (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20040077614-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | SCHERIGN AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1358881-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | Schering Aktiengesellschaft (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1358881-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | Schering Aktiengesellschaft (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003072110-A1 | USE OF BIOGENIC ESTRIOL DIESTER PRODRUGS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072110-A1 | USE OF BIOGENIC ESTRIOL DIESTER PRODRUGS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-04 | — | — | WO | disclosed |
| US-4681875-A | CONTRACEPTIVES, GYNECOLOGY | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | MAPT 4293/4885KMT2A 3205/4885MEN1 748/4885 |
| US-20040077614-A1 | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | HSD17B11, HSD17B3, HSD17B13 | MAPT 2419/4885KMT2A 3602/4885MEN1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.